相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials
Da Xu et al.
CEPHALALGIA (2019)
Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
Simona Lattanzi et al.
DRUGS (2019)
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Peter J. Goadsby et al.
BRAIN (2019)
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Peter J. Goadsby et al.
CEPHALALGIA (2019)
Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
Peter J. Goadsby et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Erenumab in chronic migraine with medication overuse Subgroup analysis of a randomized trial
Stewart J. Tepper et al.
NEUROLOGY (2019)
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
Messoud Ashina et al.
CEPHALALGIA (2019)
Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries
Eloisa Rubio-Beltran et al.
CEPHALALGIA (2019)
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Robert Croop et al.
LANCET (2019)
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
Richard B. Lipton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment
Stephen D. Silberstein et al.
HEADACHE (2019)
New Insights into the Regulation of CGRP-Family Receptors
Joseph J. Gingell et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski et al.
CEPHALALGIA (2018)
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Orit Cohen-Barak et al.
CEPHALALGIA (2018)
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
Tina Marie Myers Oakes et al.
CEPHALALGIA (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
Christophe Depre et al.
HEADACHE (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Virginia L. Stauffer et al.
JAMA NEUROLOGY (2018)
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention A Randomized Clinical Trial
Vladimir Skljarevski et al.
JAMA NEUROLOGY (2018)
The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis
Yuhan Zhu et al.
NEUROLOGICAL SCIENCES (2018)
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
Todd Schwedt et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter et al.
LANCET (2018)
Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study
Holland C. Detke et al.
NEUROLOGY (2018)
Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Bernice Kuca et al.
NEUROLOGY (2018)
Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine
Jan de Hoon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25
Debbie L. Hay et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
Zsolt Hepp et al.
CEPHALALGIA (2017)
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart Tepper et al.
LANCET NEUROLOGY (2017)
Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine
Benjamin W. Friedman et al.
NEUROLOGY (2017)
Erenumab (AMG 334) in episodic migraine Interim analysis of an ongoing open-label study
Messoud Ashina et al.
NEUROLOGY (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects
Thuy Vu et al.
PHARMACEUTICAL RESEARCH (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission
Rebecca E. Yarwood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Risk of medication overuse headache across classes of treatments for acute migraine
Kristian Thorlund et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
Licheng Shi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine
Richard B. Lipton et al.
NEUROLOGY (2015)
A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
Jeffrey L. Jackson et al.
PLOS ONE (2015)
Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program
Marcelo E. Bigal et al.
CEPHALALGIA (2014)
Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP
Marcelo E. Bigal et al.
CEPHALALGIA (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine
Benjamin W. Friedman et al.
NEUROLOGY (2014)
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Tony W. Ho et al.
NEUROLOGY (2014)
Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain
R. J. Benschop et al.
OSTEOARTHRITIS AND CARTILAGE (2014)
Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
Andrew M. Blumenfeld et al.
HEADACHE (2013)
A Prospective, Randomized Trial of Intravenous Prochlorperazine Versus Subcutaneous Sumatriptan in Acute Migraine Therapy in the Emergency Department
Mark A. Kostic et al.
ANNALS OF EMERGENCY MEDICINE (2010)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
CGRP and its receptors provide new insights into migraine pathophysiology
Tony W. Ho et al.
NATURE REVIEWS NEUROLOGY (2010)
Possible sites of action of the new calcitonin gene-related peptide receptor antagonists
Sajedeh Eftekhari et al.
Therapeutic Advances in Neurological Disorders (2010)
The acute treatment of episodic and chronic migraine in the USA
M. E. Bigal et al.
CEPHALALGIA (2009)
Design, analysis, and presentation of crossover trials
Edward J. Mills et al.
TRIALS (2009)
A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine
Benjamin W. Friedman et al.
ANNALS OF EMERGENCY MEDICINE (2008)
Metoclopramide versus hydromorphone for the emergency department treatment of migraine headache
Justin D. Griffith et al.
JOURNAL OF PAIN (2008)
Satisfaction with current migraine therapy: Experience from 3 centers in US and Sweden
Marcelo Bigal et al.
HEADACHE (2007)
Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine
David W. Dodick et al.
CNS DRUGS (2007)
A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines
BW Friedman et al.
NEUROLOGY (2005)
Consensus statement:: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine
D Dodick et al.
HEADACHE (2004)
Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials
I Colman et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
分享论文
